Investor FAQs
1.What is your revenue guidance for 2008 and 2009?
 Please check the most recent press releases and corporate presentations on our web site for the most recent guidance provided. As a reminder, the guidance was current only as of the date it was given, and we do not have an obligation to update it should our internal expectations change. The risk factors in our Form 20-F, which can be found under the Securities and Exchange filings section, will detail the risks that may cause our results to differ materially from our expectations.

Return to Top


2.When did WuXi purchase AppTec?
 We completed the AppTec purchase in January of 2008. AppTec has expanded WuXi's operations into the U.S., and its biologics and medical device testing businesses are complementary to WuXi's pharmaceutical development services.

Return to Top


3.How much did WuXi pay for AppTec?
 $151 million, including the assumption of AppTec debt of approximately $11.7 million. On the basis of AppTec’s 2007 revenue of $70 million, this price was in line with other acquisitions in our industry.

Return to Top


4.What does AppTec do?
 WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to pharmaceutical, biotechnology, and medical device companies. Our services are designed to assist our global partners in shortening the time and lowering the cost of drug and medical device R&D. We group our operations into two segments:

  • Laboratory Services
    A full range of discovery and development services for pharmaceuticals; development and testing services for biotherapeutics and medical devices; and comprehensive toxicology services.


  • Manufacturing Services
    Manufacturing Services for advanced intermediates and active pharmaceutical ingredients (APIs); cell banking and cGMP manufacturing for cellular therapeutics; and cGMP manufacturing for combination/tissue-based products.

Return to Top


5.When did WuXi go public?
 WuXi's initial public offering was completed on August 9, 2007.

Return to Top


6.How many employees does WuXi have?
 As of December, 2008, WuXi had approximately more than 3,700 employees worldwide.

Return to Top


7.Who is your ADR bank?
 WuXi PharmaTech's ADR bank is JPMorgan Chase Bank, N.A., located at 4 New York Plaza, New York, NY 10004, USA.

Return to Top


8.When does WuXi's fiscal year end?
 WuXi's fiscal year ends on December 31.

Return to Top


9.Which accounting firm audits your financial statements?
 Deloitte Touche Tohmatsu CPA Ltd. is the Company's independent auditor.

Return to Top


10.When does WuXi announce its earnings results each quarter?
 WuXi announces results in line with SEC requirements following each fiscal quarter, although the actual date may vary. The Company will provide detailed information prior to each earnings announcement through a press release and notification on the WuXi website.

Return to Top


11.What is WuXi's dividend policy?
 WuXi currently retain all available funds and and intends to retain any future earnings for use in the operation and expansion of our business. We do not anticipate paying any cash dividends on our ordinary shares, or indirectly on our ADSs, for the foreseeable future. Future cash dividends, if any, will be at the discretion of our board of directors and will depend upon our future operations and earnings, capital requirements and surplus, general financial conditions, shareholders' interests, contractual restrictions, and other factors as our board of directors may deem relevant.

Return to Top